Cargando…

Ambrisentan for the treatment of pulmonary arterial hypertension

Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasoconstrictor with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casserly, Brian, Klinger, James R
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761178/ https://www.ncbi.nlm.nih.gov/pubmed/19920913

Ejemplares similares

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
por: Casserly, Brian, et al.
Publicado: (2009)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis
por: Li, Mengtao, et al.
Publicado: (2020)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study
por: Huo, Y., et al.
Publicado: (2016)

Diagnosis and Management of Pulmonary Arterial Hypertension
por: Houtchens, Jeanne, et al.
Publicado: (2011)

Ambrisentan-induced severe asymptomatic thrombocytopenia
por: Kigitovica, Dana, et al.
Publicado: (2020)

PReS-FINAL-2267: Successful treatment of pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) with combination therapy of sildenafil and ambrisentan: a case report
por: Yamaguchi, KI, et al.
Publicado: (2013)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
por: Sato, Takahiro, et al.
Publicado: (2017)

Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model
por: Lee, Hyeryon, et al.
Publicado: (2019)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years
por: Ivy, Dunbar, et al.
Publicado: (2020)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
por: Schroeder, Thies, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
por: Mohammed, Shaadab, et al.
Publicado: (2021)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report
por: Santos, José Ramón, et al.
Publicado: (2020)

Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
Publicado: (2020)

Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial
por: Patel, Krishna R., et al.
Publicado: (2018)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
por: Pan, Zixuan, et al.
Publicado: (2019)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Pulmonary Arterial Hypertension: Pathophysiology and Treatment
por: Lan, Norris S. H., et al.
Publicado: (2018)

Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension
por: Sánchez-Gloria, José L., et al.
Publicado: (2020)

Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS
por: Lan, Tian, et al.
Publicado: (2021)

Novel Treatment Pathways in Pulmonary Arterial Hypertension
por: Qaiser, Kanza N., et al.
Publicado: (2021)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Interventional and Surgical Treatments for Pulmonary Arterial Hypertension
por: Stącel, Tomasz, et al.
Publicado: (2021)

Recent Advances in the Treatment of Pulmonary Arterial Hypertension
por: Otani, Naoyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nmrrmq93g8naubaj6h0l8j55l6